Shattuck Labs Inc expected to post a loss of 28 cents a share - Earnings Preview
28/04/2025 13:54
Shattuck Labs Inc STTK.OQ STTK.O is expected to show a fall in quarterly revenue when it reports results on April 30 (estimated) for the period ending March 31 2025 LSEG's mean analyst estimate for Shattuck Labs Inc is for a loss of 28 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts had risen by about 1.5% in the last three months. Wall Street's median 12-month price target for Shattuck Labs Inc is $2.46, above its last closing price of $0.80. Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | -0.30 | -0.32 | -0.37 | Missed | -15.8 |
| Sep. 30 2024 | -0.41 | -0.42 | -0.33 | Beat | 20.8 |
| Jun. 30 2024 | -0.42 | -0.41 | -0.42 | Missed | -1.6 |
| Mar. 31 2024 | -0.44 | -0.45 | -0.37 | Beat | 17.3 |
| Dec. 31 2023 | -0.56 | -0.57 | -0.41 | Beat | 27.8 |
| Sep. 30 2023 | -0.52 | -0.52 | -0.65 | Missed | -25.2 |
| Jun. 30 2023 | -0.52 | -0.52 | -0.50 | Beat | 3.3 |
| Mar. 31 2023 | -0.62 | -0.63 | -0.49 | Beat | 22.1 |
Recent news on Shattuck Labs
See all newsBrief: Shattuck Labs Announces Phase 2 Clinical Trial Of Sl-325 In Hidradenitis Suppurativa And Appointment Of Shoba Ravichandran, M.D., As Senior Vice President, Clinical Development
Shattuck Labs Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health